Global Market Study on Progressive Multifocal Leukoencephalopathy Treatment: HIV/AIDS Indication to Dominate in Terms of Value Through 2026 Owing to Government Initiatives and Support for HIV Associated PML Treatment


Progressive Multifocal Leukoencephalopathy Treatment  Market
  • Published On : Aug-2018 |
  • Pages : 208 Pages |
  • Format :

Progressive multifocal leukoencephalopathy (PML) is a rare viral disease characterized by progressive damage to the white matter of the brain at different locations. Progressive multifocal leukoencephalopathy destroys the brain cells that produce the protective coating (myelin) of the CNS. PML is active in about 2–6% of the people living with AIDS, generally in patients whose CD4 count is well below 100. Besides, the number of patients being recognized in the context of immunosuppressive therapies for autoimmune diseases is increasing. Furthermore, the prevalence of chronic but asymptomatic JCV infection in the general population is high. PML also occurs in patients suffering from hematological malignancies, multiple sclerosis and in patients with organ transplant.

Market Value and Forecast

The global progressive multifocal leukoencephalopathy treatment market is projected to grow at a CAGR of 2.8% throughout the forecast period (2018–2026).

Progressive Multifocal Leukoencephalopathy Treatment Market: Key Insights

  • Growing prevalence of HIV infection in several middle- and low-income economies is consequently expected to drive the growth of the market for progressive multifocal leukoencephalopathy treatment over the forecast period.
  • Growing prevalence of hematological malignancy and diagnosis of progressive multifocal leukoencephalopathy is expected to drive the growth of the progressive multifocal leukoencephalopathy treatment market over the forecast period.
  • Favorable reimbursements for HIV and cancer treatment is expected to drive the growth of the progressive multifocal leukoencephalopathy market over the forecast period.
  • Emerging treatment options such as use of anti-retroviral and antivirals are expected create lucrative growth opportunities for the new players entering the progressive multifocal leukoencephalopathy treatment market.
  • Enhancement in the testing for HIV and treatment as well as progressive multifocal leukoencephalopathy diagnosis and treatment along with the improvement in healthcare facilities and government programs is expected to spur the growth of the market for progressive multifocal leukoencephalopathy treatment over the forecast period.
  • North America, followed by Europe, is expected to be the leading regional market for progressive multifocal leukoencephalopathy treatment, owing to growing prevalence of HIV infection and hematological malignancies along with progressive multifocal leukoencephalopathy.
  • Growing awareness regarding the treatment of progressive multifocal leukoencephalopathy in underdeveloped countries such as Africa is expected to drive the growth of the market for progressive multifocal leukoencephalopathy treatment over the forecast period.
  • Asia-Pacific progressive multifocal leukoencephalopathy treatment market is projected to have continuous growth over the forecast period due to increasing prevalence of HIV infection and improving treatment rate for HIV and cancer.
  • Improving treatment-seeking rate in middle- and low-income economies and access to safe and effective treatment and timely and accurate diagnosis of cancer is further expected to increase the rate of diagnosis of progressive multifocal leukoencephalopathy
  • Use of antiviral agents, immune response modulators and immunization treatment for the potential population of progressive multifocal leukoencephalopathy is also expected to drive the growth of the market for progressive multifocal leukoencephalopathy treatment in the near future
  • Growing emphasis on the research and development of drugs and therapies for rare disease creates a huge opportunity for the market of progressive multifocal leukoencephalopathy treatment
  • Companies are trying to investigate innovative therapies aimed at control of JC virus infection instead of improving immunity which is projected to spur the growth of the progressive multifocal leukoencephalopathy treatment market over the forecast period
  • The leading companies operating in the progressive multifocal leukoencephalopathy treatment market are focusing on the improvement of the treatment available

Progressive Multifocal Leukoencephalopathy Treatment Market: Regional Outlook

The global progressive multifocal leukoencephalopathy treatment market is segmented into five key regions, namely North America, Latin America, Europe, and Asia Pacific and the Middle East & Africa. In terms of value, North America is expected to be the leading regional market for progressive multifocal leukoencephalopathy treatment and is expected to have significant growth during the forecast period. The Asia Pacific progressive multifocal leukoencephalopathy treatment market is projected exhibit significant growth over the forecast period due to increasing prevalence of HIV infection and progressive multifocal leukoencephalopathy in the region, particularly in China and India.

progressive-multifocal-leukoencephalopathy-treatment-market.jpg

Progressive Multifocal Leukoencephalopathy Treatment Market: Key Players

Examples of some of the key players operating in the global progressive multifocal leukoencephalopathy treatment market are Pfizer, Inc., GlaxoSmithKline Plc, Sanofi S.A., Gilead Sciences, Inc., Allergan Plc. (Actavis Plc.), Novartis AG, F. Hoffman - La Roche Ltd., AbbVie Inc. and Bristol-Myers Squibb Company, among others.

This Persistence Market Research (PMR) report examines the ‘Global Progressive Multifocal Leukoencephalopathy Treatment Market’ for the period 2018–2026. The primary objective of the report is to offer updates and information related to market opportunities in the global progressive multifocal leukoencephalopathy treatment market.

The Progressive Multifocal Leukoencephalopathy Treatment Market is Segmented Based on:

  • Drug Type
  • Indication
  • Distribution Channel
  • Region

This report covers the global progressive multifocal leukoencephalopathy treatment market performance in terms of revenue contribution from various segments. The global progressive multifocal leukoencephalopathy treatment market report begins with an overview and definitions. The market viewpoints section underlines macro-economic factors influencing the growth of the global progressive multifocal leukoencephalopathy treatment market along with detailed opportunity analysis of the market. This is then followed by the key drivers, restraints and trends of the global progressive multifocal leukoencephalopathy treatment market.

The global progressive multifocal leukoencephalopathy treatment market is segmented based on drug type, indication, distribution channel and regions. Based on drug type, the global progressive multifocal leukoencephalopathy treatment market is segmented into anti-retroviral therapy, antiviral/anti JCV and other symptomatic. Based on indication, the global progressive multifocal leukoencephalopathy treatment market is segmented into HIV/AIDS, organ transplantation, multiple sclerosis and hematological malignancies. Based on distribution channel, the global progressive multifocal leukoencephalopathy treatment market is segmented into hospital pharmacies, drug stores and retail pharmacies. Geographically, the global progressive multifocal leukoencephalopathy treatment market is segmented into North America (the U.S. & Canada), Latin America (Brazil, Mexico, and Rest of Latin America), Europe (Germany, France, the U.K., Italy, Spain, Russia and Rest of Europe), Asia Pacific (China, India, Australia, Japan, ASEAN and Rest of Asia Pacific), Japan and Middle-East and Africa (GCC Countries, South Africa and Rest of MEA).

A detailed analysis has been provided for each region in terms of market size, Y-o-Y growth rate, absolute $ opportunity, and market attractive index. The forecast of the progressive multifocal leukoencephalopathy treatment market by country, drug type, indication and distribution channel is represented in a tabular form for each region. This section will help to understand the present scenario and opportunities of the progressive multifocal leukoencephalopathy treatment market in major countries by each segment.

In the next section of the report, the ‘Competitive Landscape’ is included to provide report audiences with a dashboard view of the key competitor firms in order to access the key differentiators among the competitor firms. This section is primarily designed to provide clients with an objective and detailed comparative assessment of product offerings and strategies of key providers specific to a market segment. The detailed profiles of players operating in the progressive multifocal leukoencephalopathy treatment market are also provided in the report, which highlight company description, product/segment overview, SWOT analysis, financial information, key developments related to market and strategic overview.

The next section of the report highlights the market outlook for 2018–2026 and sets the forecast within the context of the progressive multifocal leukoencephalopathy treatment market by region. A detailed analysis has been provided for each region in terms of market size, Y-o-Y growth rate, absolute $ opportunity, and market attractive index.

The above sections – by drug type, indication and distribution channel – evaluate the historic market analysis and growth prospects of the progressive multifocal leukoencephalopathy treatment market for the period 2018–2026. We have considered 2017 as the base year and provided data for the forecast period.

The final section of the report represents the global scenario of the progressive multifocal leukoencephalopathy treatment market along with y-o-y growth and market forecast till 2026. This section also evaluates the global market opportunity over the forecast period as well as the absolute dollar opportunity for each year. This section will help to understand the overall growth of the progressive multifocal leukoencephalopathy treatment market and the opportunity analysis for every year over the forecast period.

To arrive at the market size, bottom-up approach is used to validate the total market size obtained for the progressive multifocal leukoencephalopathy treatment market. The forecast presented in the report provides total revenue of the progressive multifocal leukoencephalopathy treatment market over 2018–2026. PMR has used a triangulation methodology that is primarily based on experimental techniques, such as patient-level data to obtain precise market estimations for progressive multifocal leukoencephalopathy treatment market and insights on specific country/regions. The country-specific data is again analyzed to derive data at a regional level and then at the global level. This methodology ensures high quality and accuracy of information.

The factors considered while developing the estimates of the progressive multifocal leukoencephalopathy treatment market are disease epidemiology, treatment seeking rate, ratio of population prescribed with different level of treatment differently for HIV/AIDS, multiple sclerosis, organ transplant and hematological malignancies.

The average selling price (US$) is derived by using weighted average pricing methodology.

On the other hand, PMR has also analyzed the market by considering the revenue from the key players operating a segment. The key players are segmented at the tier level with respect to their revenue, product portfolio and geographical presence. This process involves analysis of various annual reports of companies, investor presentations, SEC filings, 10k reports, earning call transcripts and press releases. This task is done to fetch substantial information about the key players, their respective revenues and estimate their respective market share.

Revenue growth of the key market players is analyzed over the historical period and qualitative assessment of new treatment pattern and use of combination therapy has been made in order to validate and align the resultant market numbers. The market structure is closely studied and analyzed at the regional level to map and ascertain incremental $ opportunity for companies, for instance, supply from domestic/regional players, small-scale enterprises or unorganized segments is also taken into consideration to arrive at the final market numbers.

While forecasting the size of the progressive multifocal leukoencephalopathy treatment market, we have considered the impact of several factors such as per capital healthcare expenditure, disposable income, new testing methods and treatment pattern, generic penetration across all regions, etc. However, quantifying the market across the aforementioned segments and regions is more a matter of quantifying expectations and identifying opportunities rather than rationalizing them after the forecast has been completed. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global market.

Company Profile

  • Pfizer, Inc.
  • F. Hoffman - La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Allergan plc (Actavis plc)
  • Overview
  • Novartis AG
  • Mylan N.V.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Others.
Back To Top